Mark Taisey
About Mark Taisey
Mark J. Taisey: Senior Vice President, Global Regulatory Affairs and Strategy
Mark J. Taisey holds the title of Senior Vice President, Global Regulatory Affairs and Strategy at Amgen. In this role, he leverages his extensive experience in global regulatory affairs to ensure compliance with international regulations for Amgen’s products. His responsibilities include the development and implementation of regulatory strategies for new products. He plays an instrumental role in navigating the complex regulatory environments to bring innovative therapies to market.
Mark J. Taisey's Expertise in Global Regulatory Affairs
Taisey has extensive experience in global regulatory affairs, focusing on compliance with international regulations. His work involves collaborating with global health authorities to secure product approvals and align regulatory strategies with business objectives. By engaging in cross-functional teams, he ensures that regulatory efforts support Amgen’s goals while adhering to stringent regulatory standards worldwide.
Mark J. Taisey's Background in Pharmacovigilance and Risk Management
In addition to his regulatory affairs expertise, Taisey has a background in pharmacovigilance and risk management. This experience is critical in his role, as it allows him to effectively manage the safety and efficacy of Amgen's products. His comprehensive understanding of risk management practices enhances the company's ability to monitor and mitigate potential risks associated with their therapies.
Industry Participation and Contributions by Mark J. Taisey
Taisey actively participates in industry forums and regulatory affairs organizations to stay updated on the latest regulatory trends. His engagement in these activities allows him to contribute to the development of regulatory policies and practices within Amgen. His involvement ensures that the company remains aligned with current regulatory expectations and innovations, supporting the mission to serve patients by facilitating market access for new therapies.